阿托西班对先兆早产患者各观察指标的影响.

Objective To investigate the effects of atosiban combined with ritodrine hydrochloride on clinical efficacy, serological indicators and maternal and infant outcomes of patients with threatened premature delivery. Methods A total of 138 patients with threatened preterm delivery in the Department of Obstetrics and Gynecology of The First Affiliated Hospital of Air Force Military Medical University from June 2018 to June 2020 were collected and divided into two groups according to random number table method, with 69 patients in the control group treated with ritodrine hydrochloride and 69 patients in the study group treated with atosiban on the basis of the control group. Clinical efficacy, changes in serological indicators, maternal and child outcomes, and drug safety were compared between the two groups. Results There were 65 effective cases in the study group (94. 20%) and 56 effective cases in the control group (81. 16%). There were statistically significant differences between the two groups （P<0. 05). The study group had significantly shorter onset time of the drug and significantly longer duration of pregnancy than the control group (P<0. 05). Before treatment, there was no statistical difference in timp-1, il-8, il-6, NO and PGE2 levels between the two groups (P>0. 05). After treatment, timp-1, il-8, il-6, NO and PGE2 levels in the study group were significantly lower than those in the control group (P<0. 05). The success rate of fetal preservation, gestational age, neonatal weight and Apgar score were significantly higher in the study group than in the control group, while the rate of premature delivery was significantly lower than that in the control group (P<0. 05). The incidence of drug-induced adverse reactions (5. 80%) was significantly lower in the study group than in the control group (26. 09%)（P<0. 05). Conclusion Atosiban combined with ritodrine hydrochloride can effectively prolong pregnancy, reduce the level of serological indicators, improve maternal and infant outcomes, with fast effect, safe and significant efficacy. Therefore, it is worthy of application and promotion in the treatment of patients with threatened premature delivery. [ABSTRACT FROM AUTHOR]